Skip to main content
Premium Trial:

Request an Annual Quote

Michael Dalling, Larry Stambaugh

Premium
Benitec said this week that Michael Dalling has resigned as non-executive director of the board.
 
Dalling has been a Benitec director since March 2006, the company said.
 

 
Arrowhead Research said that Larry Stambaugh has stepped down as CEO of Arrowhead subsidiaries Insert Therapeutics and Calando Pharmaceuticals (see related story, this issue).
 
He will remain a consultant to Arrowhead, the company said.
 
Stambaugh’s departure comes amid a corporate restructuring that includes the merger of the two subsidiaries, which remains subject to Arrowhead shareholder approval.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.